The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
Abstract
Aims Recent epidemiological studies indicated that use of metformin might decrease the risk of various cancers among patients with type 2 diabetes mellitus (T2DM). However, its influence on pancreatic cancer was controversial. Therefore, we did a meta-analysis of currently available observational studies on the issue.Methods We did a PubMed and ISI Web of Science search for observational articles. The pooled relative risk (RR) was estimated using a random-effect model. Heterogeneity was evaluated using I(2) statistic. Subgroup analysis was performed to explore the source of heterogeneity and confirm the overall estimates. Publication bias was also examined.Results The analysis included 11 articles (13 studies) comprising 10 cohort studies and 3 case-control studies. Use of metformin was associated with a significant lower risk of pancreatic cancer [RR 0.63, 95% confidence internal (CI) 0.46-0.86, p=0.003]. In a total 11 subgroup analyses, 5 provided the consistent result with pooled effect estimates of overall analysis. No publication bias was detected by Begg's (Z=-0.79, p=0.428) and Egger's test (t=-0.92, p=0.378).Conclusions From present observational studies, use of metformin appears to be associated with a reduced risk of pancreatic cancer in patients with T2DM. Further investigation is needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Originally introduced for the treatment of diabetes, metformin is now gaining attention as a potential anti-cancer agent (7–10) (Figure 1).”
In the citing paper
“this finding has subsequently been confirmed in several other studies(7–10).”
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Cited by
Sorted by citations
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer
Hart, P. A., Bellin, M. D., Andersen, D. K., Bradley, D., Cruz-Monserrate, Z., Forsmark, C. E., Goodarzi, M. O., Habtezion, A., Korc, M., Kudva, Y. C., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30106-6 · Cited by 551
Diabetes, pancreatogenic diabetes, and pancreatic cancer
Andersen, D. K., Korc, M., Petersen, G. M., Eibl, G., Li, D., Rickels, M. R., Chari, S. T., & Abbruzzese, J. L. (2017) · Diabetes · doi:10.2337/db16-1477 · Cited by 516
Kordes, S., Pollak, M. N., Zwinderman, A. H., Mathôt, R. A., Weterman, M. J., Beeker, A., Punt, C. J., Richel, D. J., & Wilmink, J. W. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00027-3 · Cited by 361
Mallik, R., & Chowdhury, T. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.023 · Cited by 270
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Update on the management of pancreatic cancer: Surgery is not enough
Ansari, D., Gustafsson, A., & Andersson, R. E. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i11.3157 · Cited by 188
Yuan, S., Kar, S., Carter, P., Vithayathil, M. K., Mason, A. M., Burgess, S., & Larsson, S. C. (2020) · Diabetes · doi:10.2337/db20-0084 · Cited by 154
Xu, M., Jung, X., Hines, O. J., Eibl, G., & Chen, Y. (2018) · Pancreas · doi:10.1097/mpa.0000000000000974 · Cited by 138
Rahn, S., Zimmermann, V., Viol, F., Knaack, H., Stemmer, K., Peters, L., Lenk, L., Ungefroren, H., Saur, D., Schäfer, H., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.12.004 · Cited by 124
Pathophysiology of type 2 diabetes and the impact of altered metabolic interorgan crosstalk
Sanches, J. M., Zhao, L. N., Salehi, A. A., Wollheim, C. B., & Kaldis, P. (2021) · FEBS Journal · doi:10.1111/febs.16306 · Cited by 136
Effects of metformin on endometrial cancer: Systematic review and meta-analysis
Meireles, C. G., Pereira, S. A., Valadares, L. P., Rêgo, D. F., Simeoni, L. A., Guerra, E. N. S., & Lofrano‐Porto, A. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.120 · Cited by 118
Song, S., Wang, B., Zhang, X., Hao, L., Hu, X., Li, Z., & Sun, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134321 · Cited by 116
Diabetes and pancreatic cancer: Exploring the two-way traffic
Roy, A., Sahoo, J., Kamalanathan, S., Naik, D., Mohan, P., & Kalayarasan, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i30.4939 · Cited by 106
Ala, M., & Ala, M. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00167 · Cited by 97
Pancreatic cancer stem cell markers and exosomes - the incentive push
Heiler, S., Wang, Z., & Zöller, M. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i26.5971 · Cited by 91
Self-citationDiabetes of the exocrine pancreas
Wynne, K., Devereaux, B., & Dornhorst, A. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14451 · Cited by 87
KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops
Eibl, G., & Rozengurt, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.007 · Cited by 88
Zhang, K., Bai, P., Dai, H., & Deng, Z. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.06.001 · Cited by 84
Metabolic Profiles Associated With Metformin Efficacy in Cancer
Andrzejewski, S., Siegel, P. M., & St‐Pierre, J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00372 · Cited by 85
Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning
Gadducci, A., Biglia, N., Tana, R., Cosio, S., & Gallo, M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.06.006 · Cited by 87
New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer
Lu, Y., Rodríguez, L. A. G., Malgerud, L., González‐Pérez, A., Martín‐Pérez, M., Lagergren, J., & Bexelius, T. S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.353 · Cited by 81
Shafiei‐Irannejad, V., Samadi, N., Yousefi, B., Salehi, R., Velaei, K., & Zarghami, N. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13078 · Cited by 78
Cho, J., Scragg, R. K. R., & Petrov, M. S. (2020) · Diabetes Care · doi:10.2337/dc20-0207 · Cited by 77
Metformin: prevention of genomic instability and cancer: a review
Najafi, M., Cheki, M., Rezapoor, S., Geraily, G., Motevaseli, E., Carnovale, C., Clementi, E., & Shirazi, A. (2018) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2018.01.007 · Cited by 75
Molina‐Montes, E., Coscia, C., Gómez-Rubio, P., Fernández, A. M., Boenink, R., Rava, M., Márquez, M., Molero, X., Löhr, M. J., Sharp, L., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319990 · Cited by 79
Zhou, X., Xue, W., Ding, X., Li, L., Dou, M., Zhang, W., Lv, Z., Fan, Z., Zhao, J., & Wang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.16973 · Cited by 74
Self-citationMitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Boukalová, Š., Štursa, J., Werner, L., Ezrova, Z., Černý, J., Bezawork‐Geleta, A., Pecinová, A., Dong, L., Drahota, Z., & Neužil, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1021 · Cited by 76
The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis
Li, X., Li, T., Liu, Z., Gou, S., & Wang, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-06207-x · Cited by 74
Zhou, P., Li, B., Liu, F.-R., Zhang, M., Wang, Q., Li, Y., Xu, C., Liu, Y., Yao Zong, Y. U. A. N., & Li, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15692 · Cited by 71
Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update
Bhattamisra, S. K., Siang, T. C., Rong, C. Y., Annan, N. C., Sean, E. H. Y., Xi, L. W., Lyn, O. S., Liew, H. S., Choudhury, H., Pandey, M., et al. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190115145702 · Cited by 73
Diabetes, pancreatic cancer, and metformin therapy
Gong, J., Robbins, L., Lugea, A., Waldron, R. T., Jeon, C. Y., & Pandol, S. J. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00426 · Cited by 71
Hu, Y., Zeng, N., Ge, Y., Wang, D., Qin, X., Zhang, W., Jiang, F., & Liu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.847760 · Cited by 69
Neoplasms of the Exocrine Pancreas
Wolff, R. A., Crane, C. H., Li, D., Evans, D. B., Maitra, A., & Tsai, S. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm094 · Cited by 64
Murff, H. J., Roumie, C. L., Greevy, R. A., Hackstadt, A. J., McGowan, L. D., Hung, A. M., Grijalva, C. G., & Griffin, M. R. (2018) · Cancer Causes & Control · doi:10.1007/s10552-018-1058-4 · Cited by 65
Wan, G., Sun, X., Li, F., Wang, X., Li, C., Li, H., Yu, X., & Cao, F. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000493214 · Cited by 57
Feola, T., Puliani, G., Sesti, F. F., Modica, R., Centello, R., Minotta, R., Cannavale, G., Meglio, S. D., Vito, V. D., Lauretta, R., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01715-0 · Cited by 60
Li, W., Zhang, L., Chen, X., Jiang, Z., Zong, L., & Ma, Q. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/5190314 · Cited by 58
Abbruzzese, J. L., Andersen, D. K., Borrebaeck, C. A. K., Chari, S. T., Costello, E., Cruz‐Monserrate, Z., Eibl, G., Engleman, E. G., Fisher, W. E., Habtezion, A., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001037 · Cited by 57
Gong, J., Kelekar, G., Shen, J., Shen, J., Kaur, S., & Mita, M. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0423-z · Cited by 56
Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation
Farmer, R. E., Ford, D., Forbes, H. J., Chaturvedi, N., Kaplan, R. S., Smeeth, L. L., & Bhaskaran, K. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw275 · Cited by 53
Pancreatic Cancer and Diabetes Mellitus
Sharma, A., & Chari, S. T. (2018) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-018-0197-8 · Cited by 55
Genetic Risk Score in Diabetes Associated With Chronic Pancreatitis Versus Type 2 Diabetes Mellitus
Goodarzi, M. O., Nagpal, T., Greer, P. J., Cui, J., Chen, Y. I., Guo, X., Pankow, J. S., Rotter, J. I., Alkaade, S., Amann, S. T., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000057 · Cited by 54
Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study
Ben, Q., Zhong, J., Fei, J., Chen, H., Yv, L., Tan, J., & Yuan, Y. (2016) · Scientific Reports · doi:10.1038/srep36073 · Cited by 51
Hertzer, K. M., Xu, M., Moro, A., Dawson, D. W., Du, L., Li, G., Chang, H.-H., Stark, A. P., Jung, X., Hines, O. J., et al. (2015) · Pancreas · doi:10.1097/mpa.0000000000000497 · Cited by 53
Lee, D. Y., Yu, J. H., Park, S. H., Han, K., Kim, N. H., Yoo, H. J., Choi, K. M., Baik, S. H., Kim, N. H., & Seo, J. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-27965-2 · Cited by 48
Metformin use and prostate cancer risk
Feng, Z., Zhou, X., Liu, N., Wang, J., Chen, X., & Xu, X. (2019) · Medicine · doi:10.1097/md.0000000000014955 · Cited by 47
Zheng, W., Lai, S., Ma, N., Deng, Y., Liu, Y., Wei, D., Zhao, J.-D., & Jiang, G.-L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.08.015 · Cited by 47
Self-citationShi, Y.-Q., Zhou, X.-C., Du, P., Yin, M.-Y., Xu, L., Chen, W.-J., & Xu, C.-F. (2020) · Medicine · doi:10.1097/md.0000000000021687 · Cited by 43
Cerullo, M., Gani, F., Chen, S. Y., Canner, J., & Pawlik, T. M. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-016-3173-4 · Cited by 43
Dong, T. S., Chang, H.-H., Hauer, M., Lagishetty, V., Katzka, W. R., Rozengurt, E., Jacobs, J. P., & Eibl, G. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00170.2019 · Cited by 47
Mannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 54
Jang, W. I., Kim, M., Kang, S. H., Jo, A. J., Kim, Y. J., Tchoe, H. J., Park, C. M., Kim, H. J., Choi, J. A., Choi, H. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14525 · Cited by 41
Metformin and pancreatic cancer: Is there a role?
Souza, A. O., Khawaja, K. I., Masud, F., & Saif, M. W. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2948-8 · Cited by 43
The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective
Brocco, D., Florio, R., Lellis, L. D., Veschi, S., Grassadonia, A., Tinari, N., & Cama, A. (2020) · Cancers · doi:10.3390/cancers12071849 · Cited by 40
Lee, S. H., Yoon, S. H., Lee, H. S., Chung, M. J., Park, J. Y., Park, S. W., Song, S. Y., Chung, J. B., & Bang, S. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.12.006 · Cited by 39
Metformin with Everolimus and Octreotide in Pancreatic Neuroendocrine Tumor Patients with Diabetes
Pusceddu, S., Buzzoni, R., Vernieri, C., Concas, L., Marceglia, S. R. F., Giacomelli, L., Milione, M., Leuzzi, L., Femia, D., Formisano, B., et al. (2016) · Future Oncology · doi:10.2217/fon-2015-0077 · Cited by 38
Hu, J. K., Fan, H.-D., Gong, J., & Mao, Q.-S. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02671-0 · Cited by 34
Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know
Forsmark, C. E. (2015) · Pancreatology · doi:10.1016/j.pan.2015.11.009 · Cited by 34
Bhaw‐Luximon, A., & Jhurry, D. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2178-4 · Cited by 34
Pusceddu, S., Vernieri, C., Prinzi, N., Torchio, M., Coppa, J. C., Antista, M., Niger, M., Milione, M., Giacomelli, L., Corti, F., et al. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820927271 · Cited by 33
Júnior, A. D. D. C., Pericole, F. V., & Carvalheira, J. B. C. (2018) · Clinics · doi:10.6061/clinics/2018/e412s · Cited by 32
The exposome and pancreatic cancer, lifestyle and environmental risk factors for PDAC
Peduzzi, G., Archibugi, L., Farinella, R., Pisani, R. P. D. L., Vodičková, Ľ., Vodička, P., Kraja, B., Sáinz, J., Bars‐Cortina, D., Daniel, N., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.05.004 · Cited by 35
de Jong, R. G., Burden, A. M., de Kort, S., van Herk‐Sukel, M. P. P., Vissers, P. A. J., Janssen, P. K. C., Haak, H. R., Masclee, A., de Vries, F., & Janssen-Heijnen, M. L. G. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-16-0277 · Cited by 36
Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis
Cheng, L., Qin, T., Ma, J., Duan, W., Xu, Q., Li, X., Han, L., Li, W., Wang, Z., Zhang, D., et al. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190626120359 · Cited by 32
Self-citationMetformin - its anti-cancer effects in hematologic malignancies
Podhorecka, M. (2021) · Oncology Reviews · doi:10.4081/oncol.2021.514 · Cited by 32
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 38
The Cause and Effect Relationship of Diabetes after Acute Pancreatitis
Śliwińska‐Mossoń, M., Bil‐Lula, I., & Marek, G. (2023) · Biomedicines · doi:10.3390/biomedicines11030667 · Cited by 31
Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells
Lu, R., Yang, J., Wei, R., Ke, J., Tian, Q., Yu, F., Liu, J., Zhang, J., & Hong, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198938 · Cited by 30
Metabolic Syndrome, Type 2 Diabetes, and Cancer: Epidemiology and Potential Mechanisms
Ben-Shmuel, S., Rostoker, R., Scheinman, E. J., & LeRoith, D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_12 · Cited by 31
Metal Complex Formation and Anticancer Activity of Cu(I) and Cu(II) Complexes with Metformin
Abdelrahman, S., Alghrably, M., Campagna, M., Hauser, C. A. E., Jaremko, M., & Lachowicz, J. I. (2021) · Molecules · doi:10.3390/molecules26164730 · Cited by 29
Singh, A., Aggarwal, M., Garg, R., Stevens, T., & Chahal, P. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2090601 · Cited by 32
Cencioni, C., Malatesta, S., Benedetti, V. V., Licursi, V., Perfetto, L., Conte, F., Ranieri, D., Bartolazzi, A., Kunkl, M., Tuosto, L., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03263-w · Cited by 31
Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis
Dong, Y., Shi, Y., He, L., Cui, X.-Y., & Su, P. (2017) · Oncotarget · doi:10.18632/oncotarget.18233 · Cited by 28
Drug Repurposing in Oncology: A Systematic Review of Randomized Controlled Clinical Trials
Ioakeim‐Skoufa, I., Tobajas-Ramos, N., Menditto, E., Aza‐Pascual‐Salcedo, M., Miguel, A. G., Orlando, V., González‐Rubio, F., Fanlo, A., AZA, C. L., Ostasz, E., et al. (2023) · Cancers · doi:10.3390/cancers15112972 · Cited by 31
Targeting the Metabolic Paradigms in Cancer and Diabetes
Bosso, M., Haddad, D., Madhoun, A. S. A., & Al‐Mulla, F. (2024) · Biomedicines · doi:10.3390/biomedicines12010211 · Cited by 26
Diabetes and its Potential Impact on Head and Neck Oncogenesis
Wang, X., Wang, H., Zhang, T., Cai, L., Dai, E., & He, J. (2019) · Journal of Cancer · doi:10.7150/jca.35607 · Cited by 26
Wang, Y., Maurer, M. J., Larson, M. C., Allmer, C., Feldman, A. L., Bennani, N. N., Thompson, C. A., Porrata, L. F., Habermann, T. M., Witzig, T. E., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15997 · Cited by 24
Progress and potential of exosome analysis for early pancreatic cancer detection
Erb, U., & Zöller, M. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1187563 · Cited by 24
Moradinazar, M., Najafi, F., Rajati, F., Sarokhani, D., & Bavandpour, M. (2023) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_62_21 · Cited by 23
You, J. H., Song, S. O., Kang, M. J., Cho, Y. Y., Kim, S. W., Suh, S. H., Lee, S., Lee, Y., & Lee, B. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000254 · Cited by 22
Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management
Goodarzi, M. O., & Petrov, M. S. (2023) · Drugs · doi:10.1007/s40265-023-01913-5 · Cited by 24
Chang, H., Hsieh, C.-F., Singh, S., Tang, W., Chiang, Y.-T., & Huang, W.-F. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3770 · Cited by 21
Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment
Peters, M. L. B., Tseng, J. F., & Miksad, R. A. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.006 · Cited by 21
Using human experience to identify drug repurposing opportunities: theory and practice
Cavalla, D. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13851 · Cited by 20
Yin, W., Liu, Y., Liu, X., Ma, X., Sun, B., & Yu, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.12292 · Cited by 21
Ruze, R., Chen, Y., Xu, R., Song, J., Yin, X., Wang, C., & Xu, Q. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188844 · Cited by 19
Metformin and Pancreatic Cancer Risk in Patients With Type 2 Diabetes
Tseng, C. (2018) · Pancreas · doi:10.1097/mpa.0000000000001130 · Cited by 19
Kim, H. S., Kim, J. H., Jang, H. J., & Lee, J. Y. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.50338 · Cited by 19
Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells
Wendt, E. H. U., Schönrogge, M., Vollmar, B., & Zechner, D. (2019) · Anticancer Research · doi:10.21873/anticanres.13936 · Cited by 18
Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer
Yao, K., Zheng, H., & Li, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.942380 · Cited by 18
A phase Ib study of everolimus combined with metformin for patients with advanced cancer
Molenaar, R. J., van de Venne, T., Weterman, M. J., Mathôt, R. A. A., Klümpen, H., Richel, D. J., & Wilmink, J. W. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0478-4 · Cited by 16
Diabetes and the Pancreatobiliary Diseases
Shafqet, M. A., & Sharzehi, K. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0163-x · Cited by 16
de Villiers, E., & Hausen, H. Z. (2021) · Cancers · doi:10.3390/cancers13215407 · Cited by 16
The genetic association between type 2 diabetic and hepatocellular carcinomas
Shi, Z., Xiao, Z., Hu, L., Gao, Y., Zhao, J., Liu, Y., Shen, G., Xu, Q., & Huang, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.13 · Cited by 16
Self-citationAutophagy in cancer stem/progenitor cells
Lin, Y.-H., Huang, Y., Chen, L., & Chu, P. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2634-2 · Cited by 17
Sakaue, T., Terabe, H., Takedatsu, H., & Kawaguchi, T. (2024) · Hepatology Research · doi:10.1111/hepr.14081 · Cited by 14
Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
Zhao, Z., He, X., & Sun, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1193610 · Cited by 14
Metabolism and cancer-select topics
Lonardo, F., & Ballouk, C. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.05 · Cited by 13
Anticancer potential of metformin: focusing on gastrointestinal cancers
Khezri, M. R., Malekinejad, H., Zolbanin, N. M., & Ghasemnejad‐Berenji, M. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04256-8 · Cited by 12
Metadata
- Authors
- Wang, Z., Lai, S.-T., Xie, L., Zhao, J.-D., Ma, N.-Y., Zhu, J., Ren, Z.-G., & Jiang, G.-L.
- Affiliations
- Shanghai Medical College of Fudan University (CN)
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 106
- Issue
- 1
- Pages
- 19-26
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2160695284
- Cited by
- 176
- References
- 48
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 7 · 2023: 17 · 2022: 14 · 2021: 14 · 2020: 21 · 2019: 15 · 2018: 18 · 2017: 19 · 2016: 19 · 2015: 19 · 2014: 2
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Research and Clinical Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, pancreatic cancer, type 2 diabetes, cancer risk reduction
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Pancreatic Neoplasms, Prognosis, Case-Control Studies, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
